The 3475A-D77 trial, which was presented at the European Lung Cancer Congress (ELCC), showed that the subcutaneous ...

MSD has received approval from the European Commission (EC ... The EC's decision was influenced by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use's positive ...

China National Medical Products Administration (NMPA) has approved MSD’s KEYTRUDA for use in conjunction with platinum-containing chemotherapy as a neoadjuvant treatment and as a single agent ...